FDA.reportPublic FDA data

Anthim Purple Book BLA 125509

BLA number
125509
Proprietary names
Anthim
Proper names
obiltoxaximab
Applicant
Elusys Therapeutics, Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-09-01
Newest archive release
2026-09-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Anthimobiltoxaximab351(a)600MG/6ML (100MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2016-03-18

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-08-01U001Anthim351(a)RxElusys Therapeutics, Inc.
2020-05-01R001Anthim351(a)RxElusys Therapeutics, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Anthim351(a)RxLicensed2016-03-18